Shah Siddharth N, Das Ashok Kumar
J Assoc Physicians India. 2014 Jan;62(1 Suppl):5-9.
Ideally, the insulin therapy must aim at the creation of a near normal glycaemic profile without the barriers of unacceptable weight gain or hypoglycaemia. Provision of a flexible insulin regimen would further enhance adherence to the prescribed therapy and positively impact glycaemic control. Insulin degludec addresses many of the aspirations of ideal basal insulin. Long duration of action, flat pharmacodynamic profile, low day-to-day variability translate into benefits of predictable glucose excursions, lower risk of hypoglycaemia at same glycaemic level and effective glycaemic with one daily injection in individuals. In conclusion, insulin degludec represents an important advancement in the treatment of type 1 and 2 diabetes.
理想情况下，胰岛素治疗必须旨在建立接近正常的血糖曲线，同时避免出现体重增加不可接受或低血糖等障碍。提供灵活的胰岛素治疗方案将进一步提高对规定治疗的依从性，并对血糖控制产生积极影响。德谷胰岛素满足了理想基础胰岛素的许多期望。作用持续时间长、药效学曲线平稳、每日变化小，这转化为可预测的血糖波动、在相同血糖水平下低血糖风险较低以及个体每日注射一次即可有效控制血糖等益处。总之，德谷胰岛素代表了1型和2型糖尿病治疗的一项重要进展。
